ResearcherKindai UniversityNo recent work listed

Eri Banno

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5108-4804; OpenAlex author ID A5054052615. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2017: 1 paper

Papers 1

Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. Co-author DOI 10.3892/ijo.2017.3961 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yosuke Togashi · 1 shared paper, 2017 · strength 0.06
- Paper Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. DOI 10.3892/ijo.2017.3961 ↗
Kazuto Nishio · 1 shared paper, 2017 · strength 0.06
- Paper Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. DOI 10.3892/ijo.2017.3961 ↗
Ken Kamata · 1 shared paper, 2017 · strength 0.06
- Paper Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. DOI 10.3892/ijo.2017.3961 ↗
Masatoshi Kudo · 1 shared paper, 2017 · strength 0.06
- Paper Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. DOI 10.3892/ijo.2017.3961 ↗
Masayuki Kitano · 1 shared paper, 2017 · strength 0.06
- Paper Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. DOI 10.3892/ijo.2017.3961 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.